Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs

被引：0

作者：

Takamatsu, Hiroyuki ^{[1
]}

Matsuda, Tomohiro ^{[2
]}

Mizuno, Shohei ^{[3
]}

Takahashi, Tsutomu ^{[4
]}

Fuchida, Shin-ichi ^{[5
]}

Hanamura, Ichiro ^{[3
]}

Kataoka, Keisuke ^{[6
,7
]}

Tsukada, Nobuhiro ^{[8
]}

Matsumoto, Morio ^{[9
]}

Hangaishi, Akira ^{[10
]}

Doki, Noriko ^{[11
]}

Uchida, Naoyuki ^{[12
]}

Sawa, Masashi ^{[13
]}

Maruyama, Yumiko ^{[14
]}

Kurahashi, Shingo ^{[15
]}

Nagafuji, Koji ^{[16
]}

Harazaki, Yoriko ^{[17
,23
]}

Kako, Shinichi ^{[8
,18
]}

Iida, Shinsuke ^{[8
,19
]}

Ichinohe, Tatsuo ^{[8
,20
]}

Kanda, Yoshinobu ^{[8
,21
]}

Atsuta, Yoshiko ^{[8
,22
]}

Sunami, Kazutaka ^{[8
,24
]}

机构：

[1] Kanazawa Univ, Dept Hematol, Kanazawa, Japan

[2] Natl Canc Ctr, Inst Canc Control, Div Int Hlth Policy Res, Tokyo, Japan

[3] Aichi Med Univ, Dept Internal Med, Div Hematol, Nagakute, Japan

[4] Shimane Univ Hosp, Dept Hematol, Izumo, Japan

[5] Japan Community Hlth Care Org Kyoto Kuramaguchi Me, Dept Hematol, Kyoto, Japan

[6] Natl Canc Ctr, Res Inst, Div Mol Oncol, Tokyo, Japan

[7] Keio Univ, Sch Med, Dept Med, Div Hematol, Tokyo, Japan

[8] Japanese Red Cross Med Ctr, Div Hematol, Tokyo, Japan

[9] Natl Hosp Org Shibukawa Med Ctr, Dept Hematol, Shibukawa, Japan

[10] Natl Ctr Global Hlth & Med, Dept Hematol, Tokyo, Japan

[11] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Hematol Div, Tokyo, Japan

[12] Toranomom Hosp, Dept Hematol, Federat Natl Publ Serv Personnel Mutual Aid Assoc, Tokyo, Japan

[13] Anjo Kosei Hosp, Dept Hematol & Oncol, Anjo, Japan

[14] Univ Tsukuba Hosp, Dept Hematol, Tsukuba, Japan

[15] Toyohashi Municipal Hosp, Dept Hematol & Oncol, Toyohashi, Japan

[16] Kurume Univ Hosp, Dept Med, Div Hematol & Oncol, Kurume, Japan

[17] Miyagi Canc Ctr, Div Hematol, Natori, Japan

[18] Jichi Med Univ, Saitama Med Ctr, Div Hematol, Saitama, Japan

[19] Nagoya City Univ Hosp, Div Hematol & Oncol, Nagoya, Japan

[20] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Hematol & Oncol, Hiroshima, Japan

[21] Jichi Med Univ, Dept Med, Div Hematol, Shimotsuke, Japan

[22] Japanese Data Ctr Hematopoiet Cell Transplantat, Nagakute, Japan

[23] Aichi Med Univ, Sch Med, Dept Registry Sci Transplant & Cellular Therapy, Nagakute, Japan

[24] Natl Hosp Org Okayama Med Ctr, Dept Hematol, Okayama, Japan

来源：

HAEMATOLOGICA | 2023年 / 108卷 / 12期

关键词：

MAINTENANCE THERAPY; SURVIVAL; LENALIDOMIDE; IMPACT;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The incidence of second primary malignancies (SPM) in long-term survivors of multiple myeloma (MM) is increasing because of increased life expectancy. We retrospectively analyzed the risk factors for SPM in patients with MM after autologous stem cell transplantation (ASCT) before and after the introduction of proteasome inhibitors and immunomodulatory drugs (IMiDs). In total, 2,340 patients newly diagnosed with MM who underwent ASCT between 1995 and 2016 were enrolled in this study. Forty-three patients developed SPM (29 solid, 12 hematological, and 2 unknown tumors), with cumulative incidence rates of 0.8% and 2.5% at 24 and 60 months, respectively. The cumulative incidence rates of hematological and solid SPM at 60 months were 0.8% and 1.8%, respectively. The overall survival (OS) rate at 60 months after ASCT was 62.9% and the OS rates after the diagnosis of SPM at 24 months were 72.2% for hematological SPM and 70.9% for solid SPM. Multivariate analysis revealed that the use of IMiDs (P=0.024) and radiation (P=0.002) were significant independent risk factors for SPM. The probabilities of developing SPM and death due to other causes (mainly MM) at 60 months were 2.5% and 36.5%, respectively, indicating that the risk of SPM was lower than that of death from MM. Furthermore, SPM between the pre-novel and novel agent eras (ASCT between 2007 and 2016) groups significantly increased (1.9% vs. 4.3% at 60 months; P=0.022). The early occurrence of SPM after ASCT should be monitored cautiously.

引用

页码：3399 / 3408

页数：10

共 33 条

[31] Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents [J].

Sahebi, Firoozeh ;

Iacobelli, Simona ;

Sbianchi, Giulia ;

Koster, Linda ;

Blaise, Didier ;

Remenyi, Peter ;

Russell, Nigel H. ;

Ljungman, Per ;

Kobbe, Guido ;

Apperley, Jane ;

Trneny, Marek ;

Krejci, Marta ;

Wiktor-Jedrzejczak, Wieslaw ;

Sanchez, James F. ;

Schaap, Nicolaas ;

Isaksson, Cecilia ;

Lenhoff, Stig ;

Browne, Paul ;

Scheid, Christof ;

Wilson, Keith M. O. ;

Yakoub-Agha, Ibrahim ;

Muniz, Soledad Gonzalez ;

Schoenland, Stefan ;

Morris, Curly ;

Garderet, Laurent ;

Kroeger, Nicolaus .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (05) :930-936

[32] Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients: A Taiwan Population-Based Study [J].

Tzeng, Huey-En ;

Lin, Cheng-Li ;

Tsai, Chun-Hao ;

Tang, Chih-Hsin ;

Hwang, Wen-Li ;

Cheng, Ya-Wen ;

Sung, Fung-Chang ;

Chung, Chi-Jung .

PLOS ONE, 2013, 8 (07)

[33] Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation [J].

Yamasaki, Satoshi ;

Yoshimoto, Goichi ;

Kohno, Kentaro ;

Henzan, Hideho ;

Aoki, Takatoshi ;

Tanimoto, Kazuki ;

Sugio, Yasuhiro ;

Muta, Tsuyoshi ;

Kamimura, Tomohiko ;

Ohno, Yuju ;

Ogawa, Ryosuke ;

Eto, Tetsuya ;

Nagafuji, Koji ;

Miyamoto, Toshihiro ;

Akashi, Koichi ;

Iwasaki, Hiromi .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (01) :98-106

← 1 2 3 4 →